The treatment landscape for chronic lymphocytic leukemia (CLL) has transformed dramatically over the past decade, creating new opportunities and new questions for clinicians managing this increasingly complex disease. In this episode of the FLASCO OncoPod, FLASCO President Edgardo Santos, MD, FACP, FASCO, sits down with renowned CLL expert Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center to discuss how advances in targeted therapies are reshaping treatment decisions across the CLL continuum.

Together, they explore the evolution of CLL care from chemoimmunotherapy to modern treatment approaches centered around BTK inhibitors, BCL2 inhibitors, and anti-CD20 monoclonal antibodies. The conversation examines how molecular and genetic risk factors, including IGHV mutation status, TP53 abnormalities, and cytogenetic findings, influence first-line treatment selection and long-term management strategies.

Dr. Pinilla-Ibarz shares practical insights into the ongoing debate between fixed-duration combination regimens and continuous therapy approaches, highlighting the benefits, limitations, and patient-specific considerations that guide real-world clinical decision-making. The discussion also covers measurable residual disease (MRD), emerging MRD-guided treatment strategies, management of high-risk disease, sequencing therapies after relapse, and the growing role of next-generation BTK inhibitors.

Looking ahead, the episode explores promising therapies on the horizon, including novel BTK degraders, next-generation BCL2 inhibitors, cellular therapies, and other innovative approaches that may further improve outcomes for patients living with CLL.

Whether you are a hematologist, oncologist, advanced practice provider, or healthcare professional interested in the latest developments in blood cancers, this episode offers a comprehensive and clinically relevant update on where CLL treatment stands today and where the field is headed next.

Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting.

In this episode, Dr. Jordan reviews promising new therapies, including emerging antibody-drug conjugates and novel hormonal treatment combinations, highlights exciting clinical trial results, and discusses long-term follow-up data from the practice-changing RUBY trial.

From breakthrough research to upcoming Phase III studies that may shape the future standard of care, this conversation provides oncology professionals with key insights into the rapidly evolving treatment landscape for advanced and recurrent endometrial cancer.

What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care?

In this episode of the FLASCO OncoPod, Dr. Robin Zon joins Dr. Jorge Garcia for a thoughtful conversation about leadership, advocacy, and the launch of ASCO Edge, a new educational resource designed to help oncology professionals better understand the operational and business side of cancer care.

Dr. Zon reflects on her professional journey from community oncology practice to serving as President of ASCO, sharing how early experiences shaped her passion for empowering clinicians with the tools needed to manage practices, navigate evolving healthcare systems, and advocate for both patients and providers.

Together, they explore:

• The inspiration behind ASCO Edge

• Why business education matters in oncology

• Challenges facing modern cancer care delivery

• How oncology professionals can strengthen operational knowledge

• The importance of state societies and collaborative advocacy

• What clinicians, pharmacists, APPs, fellows, and practice leaders can gain from the platform

Designed by oncology professionals for oncology professionals, ASCO Edge offers practical, on-demand learning modules focused on real-world scenarios impacting cancer care today.

Learn more about FLASCO and upcoming educational initiatives at FLASCO.org

Get started with ASCO Edge today at https://www.asco.org/meetings-education/training-programs/asco-edge

#FLASCO #Oncology #ASCO #CancerCare #CommunityOncology #HealthcareLeadership #MedicalEducation #OncoPod #OncologyPodcast #PracticeManagement #CancerResearch #OncologyProfessionals